News Column

Studies from University of Foggia Have Provided New Information about Respiratory Disease (Nanocarriers for respiratory diseases treatment: recent...

July 23, 2014



Studies from University of Foggia Have Provided New Information about Respiratory Disease (Nanocarriers for respiratory diseases treatment: recent advances and current challenges)

By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Respiratory Disease are discussed in a new report. According to news reporting originating in Foggia, Italy, by NewsRx journalists, research stated, "Pulmonary delivery of locally-acting drugs encapsulated in nanocarriers provides several advantages for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary diseases, cystic fibrosis, tuberculosis and lung cancer. These advantages include, among others, sustained drug delivery to the lungs, reduced therapeutic dose and improved patient compliance."

The news reporters obtained a quote from the research from the University of Foggia, "The aim of this review is to give an updated overview on recent advances recorded in the last few years in this field as well as on the major challenges still existing and that remain to be overcome before any clinical application. After an outline on the cellular and extracellular barriers affecting drug delivery to the airways both in physiological and pathological conditions, the significant developments recorded using inhaled polymeric-and lipid-based nanocarriers for drug and gene delivery to the lung are presented. In this discussion, the major challenges existing in the field are evidenced including the understanding of the factors governing the mucus penetration capability of these nanocarriers and the identification of new technologies for delivering drugs to specific regions or cell types of the lungs."

According to the news reporters, the research concluded: "In this regard, the recognition of receptor expressed only at lung level may facilitate drug targeting to this organ and it should improve the therapeutic efficacy of nanocarrier-based treatments for respiratory diseases."

For more information on this research see: Nanocarriers for respiratory diseases treatment: recent advances and current challenges. Current Topics In Medicinal Chemistry, 2014;14(9):1133-47. (Bentham Science Publishers - www.benthamscience.com; Current Topics In Medicinal Chemistry - www.benthamscience.com/ctmc/index.htm)

Our news correspondents report that additional information may be obtained by contacting A. Trapani, Dept. of Medical and Surgical Sciences, University of Foggia, Viale L Pinto 1, 71122, Foggia, Italy. Additional authors for this research include S.D. Gioia, S. Castellani, A. Carbone, G. Cavallaro, G. Trapani and M. Conese (see also Respiratory Disease).

Keywords for this news article include: Italy, Foggia, Europe, Nanocarriers, Nanotechnology, Respiratory Disease, Emerging Technologies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters